Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 1;32(4):340-344.
doi: 10.1097/MCA.0000000000000976.

Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia

Chiara Schimmenti  1 , Vincenzo Sucato  2 , Elvira Manzone  1 , Giulia Cancellieri  1 , Francesca Mortillaro  1 , Giuseppina Novo  2 , Alfredo Ruggero Galassi  2 , Fabio Venturella  1
Affiliations
Review

Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia

Chiara Schimmenti et al. Coron Artery Dis. .

Abstract

Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.

PubMed Disclaimer

References

    1. Rinaldi M, Graffi G, Rabino Massa E. Metabolic syndrome and cognitive decline: the role of physical activity. J Biol Res. 2013; 86: 54–57.
    1. Arnao V, Tuttolomondo A, Daidone M, Pinto A. Lipoproteins in atherosclerosis process. Curr Med Chem. 2019; 26:1525–1543.
    1. Scharnagl H, Marz W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem. 2005; 5: 233–242.
    1. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016; 7:13457.
    1. Fenga X, Zhanga L, Xub S, Shena AZ. ATP-citratelyase(ACLY)in lipid metabolism and atherosclerosis: an updated review. Progression Lipid Res. 2020; 77:101006.

MeSH terms

Substances